Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 51655-087

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 51655-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 087 52)

This is a description of medication with NDC number 51655-087-52. The medication is called Alfuzosin Hydrochloride Extended-Release Tablets, with a strength of 10mg per tablet. The package contains 30 tablets. However, the last line is not readable and appears to be a garbled output.*

FDA Label Image

Figure 1 (Alfuzosin Fig1)

This is a description of a graph and table showing the mean alfuzosin plasma concentration-time profiles after a single administration of alfuzosin hydrochloride extended-release tablets 10 mg to 8 healthy middle-aged male volunteers in fed and fasted states. The graph displays the plasma concentration of alfuzosin over time (in hours) and shows a comparison between the fed and fasted states. The table provides numerical data regarding the alfuzosin plasma concentration in the different time intervals.*

FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

The text provides information on a clinical trial evaluating the effectiveness of Alfuzosin Hydrochloride versus a placebo in reducing IPSS Total Symptom Score. Figure 2 shows the mean change from baseline in the IPSS score after a certain number of treatment days. The results indicate that Alufuzosin Hydrochloride was significantly more effective than the placebo in reducing symptoms.*

FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

The text contains a graph titled "Mean Change from Baseline in IPSS Total Symptom Score: Trial 2" related to the "Hycom" treatment and the "DAYS OF TREATMENT" variable. The rest of the text seems to be a garbled combination of characters and is not useful for generating a description.*

FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

This is a representation of mean change from baseline in Peak Urine Flow Rate in Trial 2 after a certain number of days of treatment. The graph shows a comparison of the measurements taken before and after treatment.*

FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

The text appears to be a section of a scientific or medical study, discussing the change in peak urine flow rate for Trial 3 after a certain number of days of treatment. Without further context or information, it is difficult to provide a more detailed description of the content.*

FDA Label Image

Chemical Structure (Alfuzosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.